MA34483B1 - Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante - Google Patents

Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante

Info

Publication number
MA34483B1
MA34483B1 MA35688A MA35688A MA34483B1 MA 34483 B1 MA34483 B1 MA 34483B1 MA 35688 A MA35688 A MA 35688A MA 35688 A MA35688 A MA 35688A MA 34483 B1 MA34483 B1 MA 34483B1
Authority
MA
Morocco
Prior art keywords
treatment
hypertension
prevention
heart failure
anticoagulant therapy
Prior art date
Application number
MA35688A
Other languages
English (en)
Inventor
Diego Albrecht
Priyamvada Chandra
Sven Godtfredsen
Pierre Jordaan
Martin Lefkowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44543868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34483(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34483B1 publication Critical patent/MA34483B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des méthodes et des compositions pharmaceutiques pour le traitement de l'hypertension et/ou la prévention ou le traitement de l'insuffisance cardiaque chez un mammifère recevant une thérapie anticoagulante à l'aide d'un ou de plusieurs composés qui sont thérapeutiquement efficaces mais n'ont pas d'impact sur le ou les effets pharmacocinétiques ou pharmacodynamiques de l'anticoagulant, tels que la warfarine.
MA35688A 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante MA34483B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37641710P 2010-08-24 2010-08-24
PCT/US2011/048542 WO2012027237A1 (fr) 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque chez un mammifère recevant une thérapie anticoagulante

Publications (1)

Publication Number Publication Date
MA34483B1 true MA34483B1 (fr) 2013-08-01

Family

ID=44543868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35688A MA34483B1 (fr) 2010-08-24 2011-08-22 Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante

Country Status (17)

Country Link
US (2) US20130158088A1 (fr)
EP (1) EP2608784B1 (fr)
JP (1) JP2013536230A (fr)
KR (1) KR101864865B1 (fr)
CN (1) CN103079554A (fr)
AU (1) AU2011293648B2 (fr)
BR (1) BR112013004192A2 (fr)
CA (1) CA2807830C (fr)
CL (1) CL2013000513A1 (fr)
ES (1) ES2702529T3 (fr)
GT (1) GT201300047A (fr)
MA (1) MA34483B1 (fr)
MX (1) MX341174B (fr)
RU (1) RU2564941C2 (fr)
SG (1) SG187755A1 (fr)
TW (1) TW201208678A (fr)
WO (1) WO2012027237A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2887961T1 (sl) * 2012-08-24 2021-08-31 Novartis Ag Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju
WO2015028941A1 (fr) * 2013-08-26 2015-03-05 Novartis Ag Nouvelle utilisation
JP2016530282A (ja) * 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
TR201900360T4 (tr) * 2014-12-08 2019-02-21 Crystal Pharmatech Co Ltd Valsartan ve ahu-377 i̇çeren tri̇sodyum çok moleküllü kompleksi̇n kri̇stali̇n formlari ve bunun yöntemleri̇
JP6810152B2 (ja) 2016-02-03 2021-01-06 ノバルティス アーゲー サクビトリルおよびバルサルタンの組合せの新規使用
US20190307107A1 (en) * 2016-06-13 2019-10-10 The Board Of Regents Of The University Of Texas System Compositions and methods for modeling heart failure with preserved ejection fraction
EP3840746A1 (fr) 2018-08-23 2021-06-30 Novartis AG Nouvelle utilisation pharmaceutique pour le traitement d'une insuffisance cardiaque
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
KR102215623B1 (ko) * 2020-07-24 2021-02-15 유니셀랩 주식회사 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US6869357B2 (en) * 2001-12-19 2005-03-22 Igt Methods of conducting games of chance and gaming devices with multiple pay lines
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US7857515B2 (en) * 2007-06-15 2010-12-28 S.C. Johnson Home Storage, Inc. Airtight closure mechanism for a reclosable pouch
PT2295035T (pt) * 2007-11-06 2016-08-22 Novartis Ag Composições farmacêuticas de dupla acção com base em superestruturas de antagonista/bloqueador de receptores de angiotensina (arb) com inibidor da endopeptidase neutra (nep)

Also Published As

Publication number Publication date
AU2011293648B2 (en) 2015-02-12
EP2608784A1 (fr) 2013-07-03
GT201300047A (es) 2014-07-08
CA2807830A1 (fr) 2012-03-01
CL2013000513A1 (es) 2014-08-29
SG187755A1 (en) 2013-03-28
JP2013536230A (ja) 2013-09-19
KR20130095754A (ko) 2013-08-28
MX2013002212A (es) 2013-05-09
RU2013112859A (ru) 2014-09-27
MX341174B (es) 2016-08-10
CN103079554A (zh) 2013-05-01
RU2564941C2 (ru) 2015-10-10
EP2608784B1 (fr) 2018-09-19
US20130158088A1 (en) 2013-06-20
TW201208678A (en) 2012-03-01
ES2702529T3 (es) 2019-03-01
BR112013004192A2 (pt) 2016-05-10
US20140329872A1 (en) 2014-11-06
AU2011293648A1 (en) 2013-03-21
WO2012027237A1 (fr) 2012-03-01
CA2807830C (fr) 2018-04-03
KR101864865B1 (ko) 2018-06-05

Similar Documents

Publication Publication Date Title
MA34483B1 (fr) Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
NZ727849A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
MA42145A (fr) Triazoles agonistes du récepteur apj
MA54231B1 (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MA37808A1 (fr) Composés et leurs utilisations thérapeutiques
MA35804B1 (fr) Modulation de l'expression du virus de l'hepatite b (vhb)
MA38959A1 (fr) Modulateurs du facteur b du complément
MA34474B1 (fr) Agonistes de gpr40
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MA54386B1 (fr) Modulateurs de trex1
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA29723B1 (fr) Composes
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
EA201101231A1 (ru) Способы предотвращения или снижения риска смертности
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle